The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Vermox 100mg/5ml Oral Suspension

Johnson & Johnson (Ireland) LimitedPA0330/046/001

Main Information

Trade NameVermox 100mg/5ml Oral Suspension
Active SubstancesMebendazole
Dosage FormOral suspension
Licence HolderJohnson & Johnson (Ireland) Limited
Licence NumberPA0330/046/001

Group Information

ATC CodeP02CA Benzimidazole derivatives
P02CA01 mebendazole


License statusAuthorised
Licence Issued17/07/2009
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back